Comparative Study
Journal Article
Add like
Add dislike
Add to saved papers

Comparison of the Visian ICL and Verisyse phakic intraocular lenses for myopia from 6.00 to 20.00 diopters.

PURPOSE: To compare visual and refractive outcomes between the Visian Implantable Collamer Lens (ICL) and Verisyse phakic intraocular lens.

METHODS: Comparative interventional case series for myopia between 6.00 and 20.00 diopters (D). Thirty consecutive eyes of 16 patients had a Visian ICL implanted and 31 consecutive eyes of 19 patients had the Verisyse lens implanted. Outcomes measured at 3 months postoperatively included uncorrected visual acuity (UCVA), best spectacle-corrected visual acuity (BSCVA), and refractive predictability as well as adverse events. Preoperatively, the groups were no different in regard to age (P=.72) and spherical equivalent refraction (P=.38).

RESULTS: Postoperative UCVA of 20/20 or better and 20/25 or better in the Visian ICL group was 67% and 96%, respectively, compared to 63% and 79%, respectively, in the Verisyse lens group (P=.10). Binocular UCVA of 20/20 or better and 20/25 or better in the Visian ICL group was 92% and 100%, respectively, and in the Verisyse group, 70% and 80%, respectively (P=.007). One and two lines gain of postoperative BSCVA in the Visian ICL group was 40% and 10%, respectively, which was statistically significantly better than the Verisyse group of 16% and 6%, respectively (P=.025). Postoperative deviation from target refraction was 0.038+/-0.39 D in the Visian ICL group and -0.38+/-0.89 D in the Verisyse lens group (P=.018).

CONCLUSIONS: Monocular UCVA was similar for both groups, whereas binocular UCVA was better in the Visian ICL group. The Visian ICL group had more accurate refractive outcomes than the Verisyse lens group.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app